A carregar...
Ceritinib as a promising therapy for ALK related diseases
Ceritinib, also known as LDK-378 or Zykadia (Novartis), is a second generation inhibitor able to specifically target the anaplastic lymphoma kinase (ALK). In the last five years the interest for ALK small inhibitors grew rapidly, mainly because it was discovered that a small but significant percenta...
Na minha lista:
| Publicado no: | Transl Lung Cancer Res |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Pioneer Bioscience Publishing Company
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4367665/ https://ncbi.nlm.nih.gov/pubmed/25806325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.08.09 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|